Denver Investment Advisors Has Decreased Its Bio (TECH) Position; ZEALAND PHARMA A/S ORDINARY SHARES DENM (ZLDPF) SI Decreased By 9.17%

March 14, 2018 - By Linda Rogers

ZEALAND PHARMA A/S ORDINARY SHARES DENM (OTCMKTS:ZLDPF) had a decrease of 9.17% in short interest. ZLDPF’s SI was 59,400 shares in March as released by FINRA. Its down 9.17% from 65,400 shares previously. With 100 avg volume, 594 days are for ZEALAND PHARMA A/S ORDINARY SHARES DENM (OTCMKTS:ZLDPF)’s short sellers to cover ZLDPF’s short positions. The SI to ZEALAND PHARMA A/S ORDINARY SHARES DENM’s float is 0.26%. It closed at $15.68 lastly. It is down 0.00% since March 14, 2017 and is . It has underperformed by 16.70% the S&P500.

Denver Investment Advisors Llc decreased Bio (TECH) stake by 18.46% reported in 2017Q3 SEC filing. Denver Investment Advisors Llc sold 31,610 shares as Bio (TECH)’s stock rose 4.48%. The Denver Investment Advisors Llc holds 139,633 shares with $16.88M value, down from 171,243 last quarter. Bio now has $5.47B valuation. The stock decreased 0.35% or $0.52 during the last trading session, reaching $146.04. About 70,614 shares traded. Bio-Techne Corporation (NASDAQ:TECH) has risen 6.75% since March 14, 2017 and is uptrending. It has underperformed by 9.95% the S&P500.

Since October 10, 2017, it had 0 buys, and 2 sales for $692,499 activity. 5,000 shares were sold by Dinarello Charles A, worth $680,303 on Tuesday, February 13. On Tuesday, October 10 LUCAS ROGER C sold $12,196 worth of Bio-Techne Corporation (NASDAQ:TECH) or 100 shares.

Analysts await Bio-Techne Corporation (NASDAQ:TECH) to report earnings on May, 1. They expect $1.08 EPS, up 21.35% or $0.19 from last year’s $0.89 per share. TECH’s profit will be $40.47 million for 33.81 P/E if the $1.08 EPS becomes a reality. After $0.91 actual EPS reported by Bio-Techne Corporation for the previous quarter, Wall Street now forecasts 18.68% EPS growth.

Investors sentiment decreased to 0.98 in 2017 Q3. Its down 0.23, from 1.21 in 2017Q2. It fall, as 16 investors sold TECH shares while 86 reduced holdings. 36 funds opened positions while 87 raised stakes. 35.91 million shares or 2.04% less from 36.66 million shares in 2017Q2 were reported. Barclays Public Limited Co has invested 0% of its portfolio in Bio-Techne Corporation (NASDAQ:TECH). Morgan Stanley has 0% invested in Bio-Techne Corporation (NASDAQ:TECH) for 103,823 shares. Liberty Mutual Group Inc Asset stated it has 0.06% in Bio-Techne Corporation (NASDAQ:TECH). Fifth Third Bancshares holds 0% or 526 shares in its portfolio. Parametric Portfolio Associates Ltd Liability reported 84,252 shares. Leavell Inc holds 0.27% or 17,951 shares in its portfolio. Tygh Mgmt Inc, a Oregon-based fund reported 61,813 shares. Teacher Retirement Systems Of Texas holds 3,083 shares. 5 were accumulated by Cornerstone Advisors Inc. Vident Advisory Ltd holds 0.03% of its portfolio in Bio-Techne Corporation (NASDAQ:TECH) for 4,055 shares. Veritable Ltd Partnership owns 4,715 shares. D E Shaw Commerce Inc owns 30,684 shares or 0.01% of their US portfolio. Proshare Advisors Lc holds 0.03% or 24,297 shares. Us Bancorp De reported 0.02% of its portfolio in Bio-Techne Corporation (NASDAQ:TECH). Fmr Limited Liability Corporation stated it has 4,700 shares or 0% of all its holdings.

Denver Investment Advisors Llc increased Methode Electronics Inc (NYSE:MEI) stake by 10,985 shares to 385,749 valued at $16.34 million in 2017Q3. It also upped Silicon Motion Technol (NASDAQ:SIMO) stake by 94,279 shares and now owns 203,099 shares. Spdr S&P Oil & Gas Exp & Pr (XOP) was raised too.

Among 9 analysts covering BIO-TECHNE Corp (NASDAQ:TECH), 5 have Buy rating, 0 Sell and 4 Hold. Therefore 56% are positive. BIO-TECHNE Corp had 23 analyst reports since August 18, 2015 according to SRatingsIntel. The firm has “Hold” rating by Wells Fargo given on Thursday, July 13. The firm has “Buy” rating given on Wednesday, February 7 by Craig Hallum. As per Tuesday, February 6, the company rating was maintained by Robert W. Baird. Leerink Swann maintained the stock with “Buy” rating in Tuesday, December 5 report. As per Monday, March 27, the company rating was downgraded by Janney Capital. The stock has “Buy” rating by Robert W. Baird on Monday, October 23. The rating was maintained by Robert W. Baird with “Buy” on Tuesday, October 31. Leerink Swann reinitiated Bio-Techne Corporation (NASDAQ:TECH) on Thursday, November 10 with “Outperform” rating. The rating was upgraded by Zacks on Tuesday, August 18 to “Sell”. Citigroup initiated Bio-Techne Corporation (NASDAQ:TECH) rating on Thursday, February 9. Citigroup has “Buy” rating and $115 target.

Zealand Pharma A/S, a biotech company, engages in the discovery, design, and development of novel peptide medicines in Denmark. The company has market cap of $477.98 million. The firm markets Lixisenatide, a once-daily prandial GLP-1 peptide receptor agonist for the treatment of type 2 diabetes under the Adlyxin and Lyxumia names; and Soliqua 100/33/Suliqua, a combination of lixisenatide and insulin glargine, and a GLP-1 receptor agonist for the treatment of type 2 diabetes. It currently has negative earnings. The Company’s products under development include Glepaglutide, a novel GLP-2 analogue in Phase II clinical trials for the treatment of short bowel syndrome; Dasiglucagon, a ready-to-use hypo-pen in Phase II clinical trials to treat acute, severe hypoglycemia, as well as in Phase IIa clinical trials for pump diabetes management; Elsiglutide, a novel GLP-2 analogue in Phase II clinical trials to treat chemotherapy-induced diarrhea; and GLP1-GLU, a preclinical stage product for obesity/type 2 diabetes.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.